Cutting in on a secretase pas de deux

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Alzheimer's disease pathogenesis involves the accumulation of amyloid beta-peptide (Aβ).
• Beta-secretase (BACE1) and gamma-secretase are key enzymes responsible for Aβ production.
• The precise mechanisms regulating Aβ production are not fully understood.

Purpose of the Study:

• To investigate the direct interaction between beta-secretase and gamma-secretase.
• To identify therapeutic strategies targeting the secretase interaction to reduce Aβ production.
• To evaluate the efficacy of compounds disrupting secretase-secretase interactions.

Main Methods:

• Biochemical assays to detect protein-protein interactions between BACE1 and gamma-secretase components.
• Cell-based models of Alzheimer's disease to measure Aβ levels.
• Pharmacological screening of compounds designed to inhibit secretase-secretase complex formation.

Main Results:

• Direct physical interaction between beta-secretase and gamma-secretase was confirmed.
• Compounds disrupting this interaction significantly reduced Aβ peptide generation.
• These compounds were effective without directly inhibiting the individual enzymatic activity of BACE1 or gamma-secretase.

Conclusions:

• The interaction between beta-secretase and gamma-secretase is a critical step in Aβ production.
• Targeting this specific interaction represents a promising therapeutic avenue for Alzheimer's disease.
• Pharmacological disruption of secretase-secretase complexes offers a novel strategy for Aβ-lowering therapies.